Malaria vaccine development based on merozoite surface proteins of Plasmodium falciparum

Human Vaccines

Volumn 6, Issue 9, 2010, Pages 757-762

  Chauhan, Virander S ^a   Yazdani, Syed Shams ^a   Gaur, Deepak ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

Author keywords

Erythrocyte; Invasion; Malaria; Merozoite; Vaccine

Indexed keywords

ALUMINUM; COMBINATION A VACCINE; COMBINATION B VACCINE; FALCIPARUM MALARIA PROTEIN 1; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; LONG SYNTHETIC PEPTIDE; MALARIA VACCINE; MALARIA VACCINE MSP 1[42] C1; MALARIA VACCINE MSP PFCP2.9; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; MEROZOITE SURFACE PROTEIN 3; MEROZOITE SURFACE PROTEIN 4; MEROZOITE SURFACE PROTEIN 5; MEROZOITE SURFACE PROTEIN 6; MEROZOITE SURFACE PROTEIN 7; MEROZOITE SURFACE PROTEIN 9; MSP 1[19] EBA175 FUSION PROTEIN; MSP FU[24] FUSION PROTEIN; PARASITE ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; HUMAN; IMMUNOGENICITY; MALARIA FALCIPARUM; NOTE; PLASMODIUM FALCIPARUM; PROTEIN EXPRESSION; VIRUS LIKE AGENT;

EID: 78649390345     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.9.12468     Document Type: Note

References (43)

1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005; 434:214-7.
2. Okiro EA, Hay SI, Gikandi PW, Sharif SK, Noor AM, Peshu N, et al. The decline in paediatric malaria admissions on the coast of Kenya. Malar J 2007; 6:151.
3. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 2010; 8:272-80.
4. Enayati A, Hemingway J. Malaria management: past, present and future. Annu Rev Entomol 2010; 55:569-91.
5. Roberts L, Enserink M. Malaria. Did they really say... eradication? Science 2007; 318:1544-5.
6. Genton B. Malaria vaccines: a toy for travelers or a tool for eradication? Expert Rev Vaccines 2008; 7:597-611.
7. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007; 370:1543-51.
8. Genton B, Reed ZH. Asexual blood-stage malaria vaccine development: facing the challenges. Curr Opin Infect Dis 2007; 20:467-75.
9. Richards JS, Beeson JG. The future for blood-stage vaccines against malaria. Immunol Cell Biol 2009; 87:377-90.
10. Gaur D, Mayer DC, Miller LH. Parasite ligand-host receptor interactions during invasion of erythrocytes by Plasmodium merozoites. Int J Parasitol 2004; 34:1413-29.
11. Sanders PR, Kats LM, Drew DR, O'Donnell RA, O'Neill M, Maier AG, et al. A set of glycosylphosphatidyl inositol-anchored membrane proteins of Plasmodium falciparum is refractory to genetic deletion. Infect Immun 2006; 74:4330-8.
12. Yazdani SS, Mukherjee P, Chauhan VS, Chitnis CE. Immune responses to asexual blood-stages of malaria parasites. Curr Mol Med 2006; 6:187-203.
13. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med 2010; 7:1000218.
14. Holder AA, Freeman RR. Immunization against blood-stage rodent malaria using purified parasite antigens. Nature 1981; 294:361-4.
15. de Koning-Ward TF, O'Donnell RA, Drew DR, Thomson R, Speed TP, Crabb BS. A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies. J Exp Med 2003; 198:869-75.
16. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A, et al. Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. PLoS Clin Trials 2006; 1:34.
17. Malkin E, Long CA, Stowers AW, Zou L, Singh S, MacDonald NJ, et al. Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. PLoS Clin Trials 2007; 2:12.
18. Ellis RD, Martin LB, Shaffer D, Long CA, Miura K, Fay MP, et al. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults. PLoS One 2010; 5:8787.
19. Malkin E, Hu J, Li Z, Chen Z, Bi X, Reed Z, et al. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine 2008; 26:6864-73.
20. Smythe JA, Peterson MG, Coppel RL, Saul AJ, Kemp DJ, Anders RF. Structural diversity in the 45 kilodalton merozoite surface antigen of Plasmodium falciparum. Mol Biochem Parasitol 1990; 39:227-34.
21. Metzger WG, Okenu DM, Cavanagh DR, Robinson JV, Bojang KA, Weiss HA, et al. Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol 2003; 25:307-12.
22. Flueck C, Frank G, Smith T, Jafarshad A, Nebie I, Sirima SB, et al. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates. Vaccine 2009; 27:2653-61.
23. Sturchler D, Berger R, Rudin C, Just M, Saul A, Rzepczyk C, et al. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults. Am J Trop Med Hyg 1995; 53:423-31.
24. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 2002; 185:820-7.
25. Graves P, Gelband H. Vaccines for preventing malaria (blood-stage). Cochrane Database Syst Rev 2006; 006199.
26. Anders RF, Adda CG, Foley M, Norton RS. Recombinant protein vaccines against the asexual blood stages of Plasmodium falciparum. Hum Vaccin 2010; 6:39-53.
27. Oeuvray C, Bouharoun-Tayoun H, Grass-Masse H, Lepers JP, Ralamboranto L, Tartar A, et al. A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies. Mem Inst Oswaldo Cruz 1994; 89:77-80.
28. Hisaeda H, Saul A, Reece JJ, Kennedy MC, Long CA, Miller LH, et al. Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys. J Infect Dis 2002; 185:657-64.
29. Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, Singh S, et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med 2005; 2:344.
30. Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 2005; 73:8017-26.
31. Lusingu JP, Gesase S, Msham S, Francis F, Lemnge M, Seth M, et al. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Malar J 2009; 8:163.
32. Esen M, Kremsner PG, Schleucher R, Gässler M, Imoukhuede EB, Imbault N, et al. Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine 2009; 27:6862-8.
33. O'Donnell RA, Saul A, Cowman AF, Crabb BS. Functional conservation of the malaria vaccine antigen MSP-119 across distantly related Plasmodium species. Nat Med 2000; 6:91-5.
34. Rotman HL, Daly TM. Long CA. Plasmodium: Immunization with Carboxyl-Terminal Regions of MSP-1 Protects against Homologous but Not Heterologous Blood-Stage Parasite Challenge. Experimental Parasitology 1999; 91:78-85.
35. Valderrama-Aguirre A, Quintero G, Gómez A, Castellanos A, Pérez Y, Méndez F, et al. Antigenicity, immunogenicity and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. Am J Trop Med Hyg 2005; 73:16-24.
36. Uthaipibull C, Aufiero B, Syed SE, Hansen B, Guevara Patiño JA, Angov E, et al. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J Mol Biol 2001; 307:1381-94.
37. Mazumdar S, Mukherjee P, Yazdani SS, Jain SK, Mohmmed A, Chauhan VS. Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with humancompatible adjuvants and induction of protective immune response. Infect Immun 2010; 78:872-83.
38. Adda CG, Murphy VJ, Sunde M, Waddington LJ, Schloegel J, Talbo GH, et al. Plasmodium falciparum merozoite surface protein 2 is unstructured and forms amyloid-like fibrils. Mol Biochem Parasitol 2009; 166:159-71.
39. Lopera-Mesa TM, Kushwaha A, Mohmmed A, Chauhan VS. Plasmodium berghei merozoite surface protein-9: immunogenicity and protective efficacy using a homologous challenge model. Vaccine 2008; 26:1335-43.
40. Kushwaha A, Rao PP, Suresh RP, Chauhan VS. Immunogenicity of recombinant fragments of Plasmodium falciparum acidic basic repeat antigen produced in Escherichia coli. Parasite Immunol 2001; 23:435-44.
41. Woehlbier U, Epp C, Hackett F, Blackman MJ, Bujard H. Antibodies against multiple merozoite surface antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasion. Malar J 2010; 9:77-88.
42. Murhandarwati EE, Wang L, de Silva HD, Ma C, Plebanski M, Black CG, et al. Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection. Infect Immun 2010; 78:680-7.
43. Miura K, Zhou H, Diouf A, Moretz SE, Fay MP, Miller LH, et al. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite- surface-protein-1 antibody in inhibiting Plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol 2009; 16:963-8.